EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib

In both trials, the rate of detection of T790M mutation in patients with advanced NSCLC was approximately 63% and was unaffected by immediately prior treatment with an EGFR TKI or ethnicity.